Gottlieb A, Blauvelt A, Tha?i D, Poulin Y, Brock F, Arendt C, Boehnlein M, Reich K. Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin [Internet]. 2020Oct.27 [cited 2024Jul.22];4(6):s84. Available from: https://jofskin.org/index.php/skin/article/view/1117